NeuClone is a clinical-stage biopharmaceutical company, with an exclusive focus on the development and commercialisation of high quality biosimilar products.

 

Our Vision

Increasing affordability and patient access to life saving and life extending therapies.

 

Our Mission

Developing a diverse portfolio of clinically identical biosimilars for patients, globally.

 

Our Values

We value affordable access to healthcare, the quality and integrity of our science, and a strong patient focus.

NeuClone is a clinical-stage biopharmaceutical company, with an exclusive focus on the development and commercialisation of high quality biosimilar products.

 

Our Vision

Increasing affordability and patient access to life saving and life extending therapies.

 

Our Mission

Developing a diverse portfolio of clinically identical biosimilars for patients, globally.

 

Our Values

We value affordable access to healthcare, the quality and integrity of our science, and a strong patient focus.

WHO WE ARE

A clinical-stage biosimilar company

Our Approach

Biosimilarity, Right from the Start®

Partnering Strategy

High quality synergy with affordable manufacture, at scale to suit global need

Our Technology

Creating a cost advantage

Pipeline

Products to meet diverse, clinical needs

Our View of Biosimilars

Quality, capacity and cost are key

LATEST NEWS

SYDNEY, MAY 2018

NeuClone Announces Preclinical Results for Stelara (ustekinumab) Biosimilar Candidate

SYDNEY, JANUARY 2018

NeuClone discloses details of its fifth product: a biosimilar candidate for Prolia®/XGEVA®

BERLIN, NOVEMBER 2017

NeuClone attends the 23rd International Partnering Conference BIO-Europe

LAUSANNE, MAY 2017

NeuClone presents at the 25th ESACT Meeting

SAN FRANCISCO, JANUARY 2017

NeuClone attends the 35th Annual J.P. Morgan Healthcare Conference

COLOGNE, NOVEMBER 2016

NeuClone presents at the 22nd Annual BIO-Europe Conference

SYDNEY, AUGUST 2016

US patent granted for NeuCHO®, NeuClone’s robust cell expression system

SAN FRANCISCO, JUNE 2016

Dr. Angelo Perani presents at the 12th annual Cell Line Development and Engineering conference

SAN FRANCISCO, JUNE 2016

Dr. Russell Howard, John Oksinski and Dr. Noelle Sunstrom attend the BIO International Convention

PALM SPRINGS, MAY 2016

Dr. Noelle Sunstrom attends Cell Culture Engineering XV

SYDNEY, OCTOBER 2015

The Hon Sussan Ley MP, Minister of Health, officially opens NeuClone’s new biomanufacturing facilities

Learn more about what we do

Download NeuClone Brochure

 

Ellipse2_background-01